The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive–compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraine, attention-deficit hyperactivity disorder (ADHD), addiction, dependence, and sleep disorders. They may be prescribed alone or in combination with other medications.
The global Anti-depressant Drugs market was valued at US$ 12230 million in 2023 and is anticipated to reach US$ 13890 million by 2030, witnessing a CAGR of 2.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-depressant Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-depressant Drugs.
Report Scope
The Anti-depressant Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-depressant Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-depressant Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Alkermes
- Allergan
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- Lundbeck
- Merck
- Pfizer
- Teva Pharmaceutical Industries
- Takeda Pharmaceutical Company
- AstraZeneca
- Johnson and Johnson
- Sanofi
- Sun Pharmaceuticals
Segment by Type
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Tricyclic Antidepressant (TCA)
- Monoamine Oxidase Inhibitor (MAOI)
- Others
Segment by Application
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
- Generalized Anxiety Disorder
- Panic Disorder
- Others
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-depressant Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-depressant Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Anti-depressant Drugs Market Overview
1.1 Product Overview and Scope of Anti-depressant Drugs
1.2 Anti-depressant Drugs Segment by Type
1.2.1 Global Anti-depressant Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Selective Serotonin Reuptake Inhibitor (SSRI)
1.2.3 Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
1.2.4 Tricyclic Antidepressant (TCA)
1.2.5 Monoamine Oxidase Inhibitor (MAOI)
1.2.6 Others
1.3 Anti-depressant Drugs Segment by Application
1.3.1 Global Anti-depressant Drugs Market Value by Application: (2024-2030)
1.3.2 Major Depressive Disorder
1.3.3 Obsessive-Compulsive Disorder
1.3.4 Generalized Anxiety Disorder
1.3.5 Panic Disorder
1.3.6 Others
1.4 Global Anti-depressant Drugs Market Size Estimates and Forecasts
1.4.1 Global Anti-depressant Drugs Revenue 2019-2030
1.4.2 Global Anti-depressant Drugs Sales 2019-2030
1.4.3 Global Anti-depressant Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Anti-depressant Drugs Market Competition by Manufacturers
2.1 Global Anti-depressant Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Anti-depressant Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Anti-depressant Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Anti-depressant Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anti-depressant Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-depressant Drugs, Product Type & Application
2.7 Anti-depressant Drugs Market Competitive Situation and Trends
2.7.1 Anti-depressant Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-depressant Drugs Players Market Share by Revenue
2.7.3 Global Anti-depressant Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-depressant Drugs Retrospective Market Scenario by Region
3.1 Global Anti-depressant Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Anti-depressant Drugs Global Anti-depressant Drugs Sales by Region: 2019-2030
3.2.1 Global Anti-depressant Drugs Sales by Region: 2019-2024
3.2.2 Global Anti-depressant Drugs Sales by Region: 2025-2030
3.3 Global Anti-depressant Drugs Global Anti-depressant Drugs Revenue by Region: 2019-2030
3.3.1 Global Anti-depressant Drugs Revenue by Region: 2019-2024
3.3.2 Global Anti-depressant Drugs Revenue by Region: 2025-2030
3.4 North America Anti-depressant Drugs Market Facts & Figures by Country
3.4.1 North America Anti-depressant Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Anti-depressant Drugs Sales by Country (2019-2030)
3.4.3 North America Anti-depressant Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Anti-depressant Drugs Market Facts & Figures by Country
3.5.1 Europe Anti-depressant Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Anti-depressant Drugs Sales by Country (2019-2030)
3.5.3 Europe Anti-depressant Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-depressant Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-depressant Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Anti-depressant Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Anti-depressant Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Anti-depressant Drugs Market Facts & Figures by Country
3.7.1 Latin America Anti-depressant Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Anti-depressant Drugs Sales by Country (2019-2030)
3.7.3 Latin America Anti-depressant Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-depressant Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-depressant Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Anti-depressant Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Anti-depressant Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Anti-depressant Drugs Sales by Type (2019-2030)
4.1.1 Global Anti-depressant Drugs Sales by Type (2019-2024)
4.1.2 Global Anti-depressant Drugs Sales by Type (2025-2030)
4.1.3 Global Anti-depressant Drugs Sales Market Share by Type (2019-2030)
4.2 Global Anti-depressant Drugs Revenue by Type (2019-2030)
4.2.1 Global Anti-depressant Drugs Revenue by Type (2019-2024)
4.2.2 Global Anti-depressant Drugs Revenue by Type (2025-2030)
4.2.3 Global Anti-depressant Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Anti-depressant Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Anti-depressant Drugs Sales by Application (2019-2030)
5.1.1 Global Anti-depressant Drugs Sales by Application (2019-2024)
5.1.2 Global Anti-depressant Drugs Sales by Application (2025-2030)
5.1.3 Global Anti-depressant Drugs Sales Market Share by Application (2019-2030)
5.2 Global Anti-depressant Drugs Revenue by Application (2019-2030)
5.2.1 Global Anti-depressant Drugs Revenue by Application (2019-2024)
5.2.2 Global Anti-depressant Drugs Revenue by Application (2025-2030)
5.2.3 Global Anti-depressant Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Anti-depressant Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Alkermes
6.1.1 Alkermes Corporation Information
6.1.2 Alkermes Description and Business Overview
6.1.3 Alkermes Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Alkermes Anti-depressant Drugs Product Portfolio
6.1.5 Alkermes Recent Developments/Updates
6.2 Allergan
6.2.1 Allergan Corporation Information
6.2.2 Allergan Description and Business Overview
6.2.3 Allergan Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Allergan Anti-depressant Drugs Product Portfolio
6.2.5 Allergan Recent Developments/Updates
6.3 Bristol-Myers Squibb
6.3.1 Bristol-Myers Squibb Corporation Information
6.3.2 Bristol-Myers Squibb Description and Business Overview
6.3.3 Bristol-Myers Squibb Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Bristol-Myers Squibb Anti-depressant Drugs Product Portfolio
6.3.5 Bristol-Myers Squibb Recent Developments/Updates
6.4 Eli Lilly and Company
6.4.1 Eli Lilly and Company Corporation Information
6.4.2 Eli Lilly and Company Description and Business Overview
6.4.3 Eli Lilly and Company Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Eli Lilly and Company Anti-depressant Drugs Product Portfolio
6.4.5 Eli Lilly and Company Recent Developments/Updates
6.5 GlaxoSmithKline
6.5.1 GlaxoSmithKline Corporation Information
6.5.2 GlaxoSmithKline Description and Business Overview
6.5.3 GlaxoSmithKline Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 GlaxoSmithKline Anti-depressant Drugs Product Portfolio
6.5.5 GlaxoSmithKline Recent Developments/Updates
6.6 Lundbeck
6.6.1 Lundbeck Corporation Information
6.6.2 Lundbeck Description and Business Overview
6.6.3 Lundbeck Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Lundbeck Anti-depressant Drugs Product Portfolio
6.6.5 Lundbeck Recent Developments/Updates
6.7 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Anti-depressant Drugs Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Corporation Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Pfizer Anti-depressant Drugs Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Teva Pharmaceutical Industries
6.9.1 Teva Pharmaceutical Industries Corporation Information
6.9.2 Teva Pharmaceutical Industries Description and Business Overview
6.9.3 Teva Pharmaceutical Industries Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Teva Pharmaceutical Industries Anti-depressant Drugs Product Portfolio
6.9.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.10 Takeda Pharmaceutical Company
6.10.1 Takeda Pharmaceutical Company Corporation Information
6.10.2 Takeda Pharmaceutical Company Description and Business Overview
6.10.3 Takeda Pharmaceutical Company Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Takeda Pharmaceutical Company Anti-depressant Drugs Product Portfolio
6.10.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.11 AstraZeneca
6.11.1 AstraZeneca Corporation Information
6.11.2 AstraZeneca Anti-depressant Drugs Description and Business Overview
6.11.3 AstraZeneca Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 AstraZeneca Anti-depressant Drugs Product Portfolio
6.11.5 AstraZeneca Recent Developments/Updates
6.12 Johnson and Johnson
6.12.1 Johnson and Johnson Corporation Information
6.12.2 Johnson and Johnson Anti-depressant Drugs Description and Business Overview
6.12.3 Johnson and Johnson Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Johnson and Johnson Anti-depressant Drugs Product Portfolio
6.12.5 Johnson and Johnson Recent Developments/Updates
6.13 Sanofi
6.13.1 Sanofi Corporation Information
6.13.2 Sanofi Anti-depressant Drugs Description and Business Overview
6.13.3 Sanofi Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Sanofi Anti-depressant Drugs Product Portfolio
6.13.5 Sanofi Recent Developments/Updates
6.14 Sun Pharmaceuticals
6.14.1 Sun Pharmaceuticals Corporation Information
6.14.2 Sun Pharmaceuticals Anti-depressant Drugs Description and Business Overview
6.14.3 Sun Pharmaceuticals Anti-depressant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Sun Pharmaceuticals Anti-depressant Drugs Product Portfolio
6.14.5 Sun Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-depressant Drugs Industry Chain Analysis
7.2 Anti-depressant Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-depressant Drugs Production Mode & Process
7.4 Anti-depressant Drugs Sales and Marketing
7.4.1 Anti-depressant Drugs Sales Channels
7.4.2 Anti-depressant Drugs Distributors
7.5 Anti-depressant Drugs Customers
8 Anti-depressant Drugs Market Dynamics
8.1 Anti-depressant Drugs Industry Trends
8.2 Anti-depressant Drugs Market Drivers
8.3 Anti-depressant Drugs Market Challenges
8.4 Anti-depressant Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
